re: question for stolwyk / jovel1 Hi Jovel,The problem with...

re: question for stolwyk / jovel1 Hi Jovel,

The problem with Biotechs in the market is that they have been in the main badly treated: People tend to have a very short term horizon.

Some drugs are heavily underrated IMHO.

In a status quo position, those stocks suffer till such time a trial is announced or any other important event takes place.

On the other hand, stocks eg CST and now MBP are moving. The first expects 2 Approvals shortly and will then market a new diagnostic while MBP did get an uplift from that Investment Report and the Phase II trial will complete in Sept.

I am expecting big things from this fat-lowering drug, provided Phase II is successful.

The new trial of PBT-2 won't start till much later in the year. This will involve a more powerful drug than PBT-1.

I don't know the precise starting time. It could be at year-end perhaps.

At the moment I am half-strength in PBT but will buy more shortly perhaps because the share price must be getting close to the bottom, IMHO.

I'll still have to wait till there is an Announcement about progress. It is likely a couple will come through before the actual trial. One of these ought to deal with PBT-2.

I have the patience and don't need the cash.

What you want to do, is your business of course.

But keep in touch in case you decide to hold.

That is my opinion,

Gerry
Readers, please do your own research and you decide if and when to buy, hold or sell any stocks.